Drug Trial Radar · NCT04810078
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
681
Actual
Start
May 21, 2021
Primary completion
Jul 29, 2025
Study completion May 10, 2027
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Mar 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab in participants with previously treated clear cell renal cell carcinoma that is advanced or has spread. The purpose of this study's substudy is to evaluate drug level biocomparability of subcutaneous nivolumab manufactured using two different manufacturing processes.
Conditions
- Clear Cell Renal Cell Carcinoma
Interventions
Nivolumab and rHuPH20Biological
Specified dose on specified days
NivolumabBiological
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original ScaleTime frame: Pre-dose (Day 1 to Day 28)
- Adjusted Geometric Mean of Nivolumab Trough Serum Concentration at Steady State (Cminss) on Original ScaleTime frame: Pre-dose (Day 1 to Day 28)
Locations
89 sites in 17 countries. Site status is shown where the registry gives one.
Local Institution
Chicago, Illinois
Local Institution - 0025
Buffalo, New York
Local Institution - 0088
West Reading, Pennsylvania
Local Institution - 0038
Buenos Aires, Buenos Aires, Argentina
Local Institution - 0095
Capital Federal, Buenos Aires, Argentina
Local Institution - 0058
Mar del Plata, Buenos Aires, Argentina
Local Institution - 0037
Pergamino, Buenos Aires, Argentina
Local Institution - 0079
Parana, Córdoba Province, Argentina
Local Institution - 0030
Río Cuarto, Córdoba Province, Argentina
Local Institution - 0066
Viedma, Río Negro Province, Argentina
Local Institution - 0056
San Juan, San Juan Province, Argentina
Local Institution - 0064
Curitiba, Paraná, Brazil
Local Institution - 0090
Rio de Janeiro, Rio de Janeiro, Brazil
Local Institution - 0107
Ijuí, Rio Grande do Sul, Brazil
Local Institution - 0039
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 0071
Barretos, São Paulo, Brazil
Local Institution - 0070
São José do Rio Preto, São Paulo, Brazil
Local Institution - 0081
São Paulo, São Paulo, Brazil
Local Institution - 0096
São Paulo, São Paulo, Brazil
Local Institution - 0084
Temuco, Araucania, Chile
Local Institution - 0005
Santiago, Santiago Metropolitan, Chile
Local Institution - 0104
Santiago, Santiago Metropolitan, Chile
Local Institution - 0076
Santiago, Santiago Metropolitan, Chile
Local Institution - 0077
Viña del Mar, Valparaiso, Chile
Local Institution - 0063
Brno, Czechia
Local Institution - 0036
Hradec Králové, Czechia
Local Institution - 0020
Olomouc, Czechia
Local Institution - 0099
Ostrava, Czechia
Local Institution - 0010
Prague, Czechia
Local Institution - 0106
Praha 8 Liben, Czechia
Local Institution - 0017
Tampere, Finland
Local Institution
Nice, France
Local Institution - 0051
Suresnes, France
Local Institution - 0068
Villejuif, France
Local Institution - 0060
Tallaght, Dublin, Ireland
Local Institution - 0033
Cremona, Italy
Local Institution - 0008
Florence, Italy
Local Institution - 0027
Meldola, Italy
Local Institution - 0018
Milan, Italy
Local Institution
Milan, Italy
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.